Navigation Links
HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen University's School of Pharmaceutical Sciences
Date:8/30/2010

SAN DIEGO, Aug. 30 /PRNewswire/ -- HUYA Bioscience International, a company at the forefront of globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU).  The collaborative agreement expands HUYA's foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school's research efforts.

The agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by SYSU's School of Pharmaceutical Sciences.  Correspondingly, the school gains access to HUYA's expertise in drug development as well as its global network of pharmaceutical partners.

HUYA is one of the first companies to have recognized China's potential to help meet the global needs for new preclinical and clinical stage compounds.  This partnership is one of a series of collaborations that HUYA has established with leading academic and commercial R&D organizations throughout China in order to bring promising new drugs to global markets.  The company has pioneered in-licensing clinical stage compounds from China and is co-developing them concurrently in the U.S. and China with international partners.

The School of Pharmaceutical Sciences at SYSU, a prominent school in southern China, has the top per-capita research funding among China's pharmaceutical colleges and the capabilities to perform cutting-edge research as well as preclinical and clinical studies.  Research results at the school have been recognized internationally and have won numerous national and provincial awards, including China's state funding for Key Projects on Innovative Drug Discovery. These activities have provided rich sources of novel drug candidates.

"The alliance with the School of Pharmaceutical Sciences at SYSU bolsters our collaborative relationships with the school's outstanding faculty and researchers," said Mireille Gingras, Ph.D., President and CEO of HUYA.  "We believe our combined efforts will not only benefit the growth of both organizations, but also yield product opportunities of high potential to meet global medical needs."

"Our school is committed to internationalizing and commercializing the achievements of our research work," remarked Professor Min Huang, Ph.D., Dean of SYSU's School of Pharmaceutical Sciences.  "We are very pleased to join forces with the HUYA team to reach the goals by sharing our respective expertise and co-developing promising compounds."

ABOUT HUYA BIOSCIENCE INTERNATIONALHUYA is the leader in global co-development of pharmaceutical products originating in China. With six offices strategically located in China, the most comprehensive Chinese compound portfolio, and a fast growing number of exclusive agreements with premier Chinese research and development organizations, HUYA has pioneered the most innovative and productive approach to U.S.-China pharmaceutical co-development.  HUYA offers Western pharmaceutical companies efficient access to innovative drug opportunities and reduces complexity in making deals in China.  The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China.  Additional information about the company is available at www.huyabio.com.

ABOUT THE SCHOOL OF PHARMACEUTICAL SCIENCES, SUN YAT-SEN UNIVERSITY The School of Pharmaceutical Sciences, Sun Yat-sen University (SYSU) was established in 2002 as the first school newly formed after the combination of two universities--SYSU and SYSU of Medicinal Sciences.  It thus leverages all the medicinal research resources from both universities.  In order to develop into a national center for innovative drug research, development and evaluation as well as a training base for professionals in pharmacy, the school has been enriching its disciplines, recruiting outstanding teaching and research personnel, strengthening its infrastructure and logistics, and fostering a culture of creativity.  Through these efforts the school has achieved remarkable results including many award-winning projects.  It has also earned a key leading role in building the Southern China Center for Innovative Pharmaceuticals sponsored by the Guangdong Province.  For more information, visit http://sps.sysu.edu.cn.CONTACT:USA:Yung-Chih Wang, Ph.D., MBADirector of Corporate DevelopmentHUYA Bioscience International, LLC+1.858.798.8800ywang@huyabio.comChina:Qing (Vicky) Xia, MS, MBAScientific Research ManagerHUYA Bioscience International, LLC+86.21.51323312vxia@huyabio.comMedia Contact:Juliet Travis+1.510.452.3771juliet@travispr.com
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
2. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
3. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
4. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
5. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
11. Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):